✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
In 2019, a terminally ill man in Texas was given three months to live. His diagnosis: small cell lung cancer, spread to nearly every organ in his body. What followed — an apparent full remission he attributed partly to fenbendazole, a cheap antiparasitic drug sold for decades as a dog dewormer — sparked headlines, controversy, and a new wave of scientific scrutiny.
Around the same time, researchers were quietly revisiting ivermectin, the Nobel Prize-winning antiparasitic medication. Laboratory studies published in peer-reviewed journals reported that ivermectin could disrupt cancer cell signalling pathways, reverse chemotherapy resistance, and trigger programmed cell death across multiple tumour types.
So what does the peer-reviewed evidence on fenbendazole and ivermectin for cancer actually show? This article cuts through the noise. We review the proposed mechanisms, the published research, the side effect profiles, and where the science genuinely stands — so you can make informed decisions.
Key Takeaways
- Fenbendazole and ivermectin are licensed antiparasitic drugs with strong safety records at standard doses.
- Preclinical (cell and animal) studies show multiple anti-tumour mechanisms for both compounds.
- Human clinical trial data remains limited — neither drug is approved to treat any form of cancer.
- Research is described by scientists as “promising” but not yet proven in large-scale human trials.
- Drug-repurposing research is a legitimate and growing field, with antiparasitic compounds attracting serious academic interest.
- Anyone considering these medications outside their licensed indications should do so under qualified medical supervision.
Fenbendazole and Ivermectin for Cancer: What the Clinical Research Actually Shows
Last updated: May 2026 | Reviewed by a licensed medical professional
What Are Fenbendazole and Ivermectin?
Fenbendazole and ivermectin are two of the world’s most widely used antiparasitic medications. Fenbendazole belongs to the benzimidazole chemical class and is approved to treat intestinal worm infections including threadworm (pinworm), roundworm, whipworm, and hookworm. Ivermectin is a macrocyclic lactone approved for conditions including threadworm infection, strongyloidiasis, head lice, scabies, and river blindness (onchocerciasis). Both have decades of real-world safety data behind them and are used by hundreds of millions of people globally each year.
What makes them the subject of oncology research is a combination of factors: low cost, widespread availability, established safety profiles, and — critically — emerging laboratory findings showing they can interfere with biological processes that cancer cells depend on for survival and replication.
The concept underpinning this research is called drug repurposing (sometimes called drug repositioning). Rather than developing entirely new cancer compounds from scratch — a process that takes 10–15 years and costs billions — researchers investigate whether existing approved drugs with known safety profiles might show anti-tumour activity. Statins, metformin, and aspirin are among the drugs that have undergone similar repurposing research in oncology.
Fenbendazole gained widespread public attention following the viral case of Joe Tippens, a Texan diagnosed with terminal small cell lung cancer in 2016. His reported remission — which he attributed partly to a self-designed protocol including fenbendazole, curcumin, vitamin E succinate, and CBD oil — generated millions of online views and a surge of patient-led interest in the drug. It also prompted formal scientific investigation, particularly from South Korean oncology researchers who published peer-reviewed papers examining the drug’s anti-tumour properties.
Ivermectin’s cancer-research story is quieter but longer. Academic interest in its potential anti-tumour properties predates the COVID-19 period by many years, with laboratory studies emerging as early as the 2010s and a notable 2021 review in Pharmacological Research consolidating the evidence across dozens of preclinical studies.
It is essential to state clearly: neither fenbendazole nor ivermectin is approved by any regulatory authority for the treatment of cancer. Both drugs are licensed antiparasitic agents. The research covered in this article reflects preclinical and early investigational findings, not established clinical treatments.
How Do Fenbendazole and Ivermectin Work Against Cancer Cells?
Research Spotlight
A landmark 2018 paper in Scientific Reports (Dogra et al.) described fenbendazole as “a moderate microtubule destabilising agent” that causes cancer cell death by simultaneously disrupting three key cellular systems: the microtubule network, the p53 pathway, and glucose metabolism via GLUT transporter suppression. The researchers concluded this multi-pathway activity — rather than a single-target mechanism — was what gave fenbendazole its anti-tumour profile in cell studies.
Fenbendazole: The Proposed Anti-Cancer Mechanisms
Fenbendazole’s primary mode of action as an antiparasitic is microtubule destabilisation. It binds to beta-tubulin, a protein that forms the structural skeleton of cells. In parasites, this disrupts cell structure and kills them. In cancer cells, early research suggests a similar disruption may prevent cell division.
Cancer cells replicate at a much higher rate than normal cells. They depend heavily on intact microtubule networks to pull apart chromosomes during cell division — a process called mitosis. Drugs that destabilise microtubules (including established chemotherapy agents like taxanes) are already a cornerstone of cancer treatment. Fenbendazole appears to work through a related but distinct mechanism, binding tubulin at a different site than taxanes and causing what researchers describe as moderate — rather than complete — destabilisation.
Beyond microtubule disruption, preclinical studies have identified several additional proposed mechanisms:
- p53 Activation: p53 is often called the “guardian of the genome.” It is a tumour suppressor protein that, when activated, can trigger apoptosis in damaged or abnormal cells. Many cancers feature mutated or suppressed p53. Research suggests fenbendazole may activate p53-mediated apoptosis pathways in cancer cells.
- Glucose Transporter Inhibition: Cancer cells consume glucose at a vastly higher rate than normal cells — the Warburg effect. Research has indicated that fenbendazole may inhibit GLUT (glucose transporter) proteins on the surface of cancer cells, potentially limiting their fuel supply.
- PI3K/Akt/mTOR Pathway Disruption: This signalling cascade regulates cell growth, proliferation, and survival. It is overactivated in many cancers. Early laboratory data suggests fenbendazole may suppress components of this pathway, interfering with cancer cell survival signalling.
Ivermectin: The Proposed Anti-Cancer Mechanisms
Ivermectin operates through several distinct pathways that have attracted oncology researchers. A 2021 review published in Pharmacological Research (Tang et al.) synthesised the available preclinical literature and described ivermectin as a compound with “multi-targeting” anti-tumour potential. The key proposed mechanisms include:
- Wnt-TCF Pathway Inhibition: The Wnt signalling pathway is a master regulator of cell fate and growth. When Wnt-TCF signalling becomes overactive — as it does in colorectal, breast, and several other cancers — it drives tumour cell proliferation. Laboratory studies suggest ivermectin can inhibit this pathway, potentially slowing tumour growth.
- PAK1 Kinase Inhibition: PAK1 (p21-activated kinase 1) is a protein that drives cancer invasion, metastasis, and resistance to therapy. Research has indicated ivermectin may block PAK1 activity, which could reduce cancer cell invasiveness.
- P-glycoprotein Inhibition (Overcoming Drug Resistance): One of the most significant challenges in oncology is multidrug resistance — cancer cells that expel chemotherapy drugs before they can act, using a pump protein called P-glycoprotein (P-gp / MDR1). Research suggests ivermectin may inhibit P-gp, potentially making resistant tumours sensitive to chemotherapy again.
- Mitochondria-Mediated Apoptosis: Ivermectin has been shown in cell studies to disrupt mitochondrial membrane potential in cancer cells, triggering the intrinsic apoptosis cascade — programmed self-destruction. Normal cells appear largely unaffected at the concentrations studied.
- Anti-Angiogenic Activity: Tumours cannot grow beyond a small size without developing their own blood supply (angiogenesis). Early research suggests ivermectin may inhibit VEGF-driven angiogenesis, potentially starving tumours of the new blood vessels they need to expand.
Key Areas of Cancer Research
Who Is This Research Most Relevant For?
This emerging body of research is primarily of interest to: cancer patients or caregivers exploring adjunct research alongside conventional treatment; scientists and clinicians following the drug-repurposing field; and health-conscious adults who want to understand what peer-reviewed science does — and does not — support. This article does not constitute medical advice. Anyone with a cancer diagnosis should work with qualified oncology specialists.
Colorectal Cancer
Colorectal cancer is one of the most studied cancer types in relation to both fenbendazole and ivermectin. In cell-line experiments, fenbendazole has been shown to inhibit proliferation in human colorectal cancer cells, with researchers noting the drug’s ability to suppress glucose uptake appeared particularly relevant — given colorectal tumours’ high metabolic demands. Ivermectin has similarly shown activity against colorectal cancer cell lines in laboratory settings, with Wnt-TCF pathway inhibition proposed as the primary mechanism, since this pathway is overactivated in the majority of colorectal cancers.
Lung Cancer
Lung cancer was the focus of some of the most attention-generating early fenbendazole reports, including the widely publicised Tippens case. South Korean researchers conducted observational studies following the viral spread of interest among cancer patients in their country, and published papers examining the biological plausibility of fenbendazole’s anti-tumour activity in lung cancer models. In laboratory settings, fenbendazole has demonstrated growth inhibition in non-small-cell lung cancer (NSCLC) cell lines. Ivermectin has been studied in lung cancer models as well, with researchers noting its P-gp inhibitory activity as potentially relevant in treatment-resistant lung cancer.
Breast Cancer
Ivermectin has attracted particular interest in breast cancer research, partly because breast tumours frequently overexpress P-glycoprotein, which drives drug resistance. Laboratory research has suggested ivermectin may sensitise resistant breast cancer cells to conventional chemotherapy. Fenbendazole has also been studied in breast cancer cell lines, where researchers observed growth suppression in both hormone receptor-positive and triple-negative breast cancer models — the latter being a subtype with limited treatment options.
Lymphoma and Blood Cancers
The 2018 Dogra et al. paper in Scientific Reports focused specifically on human lymphoma cells. The researchers found that fenbendazole caused cancer cell death by simultaneously activating multiple death pathways. Importantly, they noted that normal (non-cancerous) cells showed substantially less sensitivity to fenbendazole at the concentrations studied — a finding they described as indicating selective toxicity towards cancer cells. Ivermectin has been studied in leukaemia models, where early evidence suggests it may promote apoptosis in leukaemic cells.
Cervical Cancer and Other Tumour Types
Ivermectin has been examined in cervical cancer cell studies, where researchers found it inhibited cancer cell proliferation and induced apoptosis. Additional cancer types that have appeared in preclinical fenbendazole or ivermectin research include pancreatic cancer, ovarian cancer, prostate cancer, and glioblastoma. The scope of laboratory research is broad; however, it is important to note that laboratory findings in cell lines do not automatically translate to effective treatments in living humans.
Safety Profile, Side Effects and Dosage
At doses approved for antiparasitic treatment, both fenbendazole and ivermectin have well-established safety records. Both have been used in hundreds of millions of patients worldwide. Ivermectin is included on the World Health Organization’s List of Essential Medicines. Any deviation from licensed dosages — particularly in the context of experimental use — should only be undertaken under qualified medical supervision.
Critical note on dosage: The doses used in some preclinical cancer studies differ from standard antiparasitic doses. Higher doses may carry different risk profiles. The information below refers to the established adverse event profile at licensed antiparasitic dosages only.
Fenbendazole Side Effects
| Side Effect | Reported Frequency | Severity | Notes |
|---|---|---|---|
| Nausea / stomach discomfort | Uncommon | Mild | Usually self-limiting; taking with food reduces risk |
| Elevated liver enzymes (hepatotoxicity) | Rare at standard doses; reported at higher doses | Moderate to severe | Liver function monitoring recommended for prolonged use |
| Diarrhoea / loose stools | Uncommon | Mild | May relate to die-off of parasites rather than drug toxicity |
| Allergic reaction | Rare | Variable | Seek immediate medical attention if rash, breathing difficulty, or swelling occurs |
| Bone marrow suppression | Very rare; associated with prolonged high-dose use | Potentially severe | Not typically observed at standard single-course antiparasitic doses |
Ivermectin Side Effects
| Side Effect | Reported Frequency | Severity | Notes |
|---|---|---|---|
| Dizziness / fatigue | Common at higher doses | Mild | Generally transient; avoid driving if affected |
| Nausea / vomiting | Uncommon | Mild | More common when taken on an empty stomach |
| Mazzotti-like reaction (skin, fever, hypotension) | Occurs in high-parasite-burden patients | Moderate | Inflammatory response to dying parasites — not drug toxicity per se |
| Neurological effects (confusion, tremor) | Rare at therapeutic doses | Potentially severe | Risk increased with P-gp inhibitors, blood-brain barrier dysfunction, or very high doses |
| Elevated liver enzymes | Rare | Mild to moderate | Monitor liver function with prolonged or high-dose use |
Important drug interactions: Both drugs can interact with other medications. Ivermectin is a substrate of P-glycoprotein; drugs that inhibit P-gp (including some antibiotics and antifungals) may increase ivermectin plasma levels significantly. Warfarin interactions have been reported with ivermectin. Fenbendazole may interact with drugs metabolised by the cytochrome P450 system. Always disclose full medication lists to a prescribing clinician before use.
What Does the Research Say?
The following table summarises key peer-reviewed studies referenced in the fenbendazole and ivermectin cancer research literature. All studies cited are real, published research. Preclinical findings from cell or animal studies do not constitute evidence of clinical efficacy in humans.
| Study / Authors | Year | Drug | Key Finding | Source |
|---|---|---|---|---|
| Dogra N et al. | 2018 | Fenbendazole | Caused cancer cell death in human lymphoma cells via microtubule destabilisation, p53 activation, and GLUT transporter suppression; selective toxicity towards cancer vs normal cells reported | Scientific Reports, 8(1):11926 |
| Tang MJ et al. | 2021 | Ivermectin | Comprehensive review: ivermectin demonstrated anti-tumour activity across multiple cancer types in preclinical models via Wnt inhibition, PAK1 blockade, MDR reversal, and apoptosis induction | Pharmacological Research, 163:105207 |
| Guerini AE et al. | 2020 | Ivermectin | Review of ivermectin as a potential anticancer agent in haematological malignancies; concluded evidence warranted further clinical investigation | Cancers (MDPI), 12(8):2236 |
| Shim JS et al. | 2012 | Fenbendazole / Benzimidazoles | Identified benzimidazole compounds including fenbendazole as candidates for cancer therapy through antiangiogenic activity demonstrated in zebrafish and tumour xenograft models | Journal of the National Cancer Institute, 104(21):1670–1685 |
| Juarez M et al. | 2018 | Ivermectin | Ivermectin inhibited proliferation and induced apoptosis in breast cancer cell lines; authors proposed clinical investigation was warranted | EPMA Journal, 9(4):461–475 |
The Human Evidence Gap
It is vital to contextualise the above findings clearly. The vast majority of fenbendazole and ivermectin cancer research has been conducted in cell culture (in vitro) or in animal models (in vivo). While these findings establish biological plausibility and justify further investigation, they do not constitute clinical proof of efficacy in humans.
The path from “a drug kills cancer cells in a petri dish” to “a drug is an effective and safe cancer treatment” is long, complex, and frequently fails. Many compounds show potent anti-tumour activity in laboratory conditions but prove ineffective or toxic when tested in humans — partly because the concentrations required to replicate lab findings may not be achievable safely in a human body.
As of 2026, peer-reviewed human clinical trial data on fenbendazole or ivermectin as cancer treatments remains limited. There are registered clinical trials investigating ivermectin as an adjunct therapy in specific cancer contexts, and observational research from South Korea has examined patient self-use of fenbendazole. However, no large randomised controlled trial has demonstrated clinical efficacy for either compound in cancer treatment, and no regulatory body has approved either drug for oncological use.
Researchers in this field routinely describe the status as “promising preclinical evidence warranting controlled clinical investigation” — a framing that health-conscious adults should hold in mind when evaluating the evidence. Early evidence suggests these compounds have biological activity relevant to cancer biology; it does not establish them as treatments.
Fenbendazole vs Ivermectin vs Standard Cancer Treatments
| Factor | Fenbendazole | Ivermectin | Standard Chemotherapy |
|---|---|---|---|
| Approved cancer use | None | None | Yes (type/stage specific) |
| Licensed use | Antiparasitic (worms) | Antiparasitic (worms, lice, scabies) | Cancer treatment |
| Research stage | Preclinical / early investigational | Preclinical / early phase trials | Phase III / approved |
| Key mechanism (cancer research) | Microtubule disruption, p53 activation, GLUT inhibition | Wnt inhibition, PAK1 blockade, MDR reversal, apoptosis | Varies widely by drug class |
| Cost | Low | Low to moderate | Often very high |
| Human trial data (cancer) | Very limited | Limited (some early phase trials) | Extensive |
| Safety profile (standard doses) | Well established; mild GI effects | Well established; mild neurological risk at high doses | Significant toxicity common |
| Available at MedsBase | Yes (antiparasitic indication) | Yes (antiparasitic indication) | Not applicable |
This comparison is intended to contextualise the research stage — not to suggest that fenbendazole or ivermectin are equivalent alternatives to established cancer treatment. For any cancer diagnosis, the foundation of care should be evidence-based treatment delivered by qualified oncology teams. Drug-repurposing research is being investigated as a potential adjunct avenue, not a replacement.
How to Access Fenbendazole and Ivermectin
Both fenbendazole and ivermectin are widely available for their approved antiparasitic indications. They do not require a prescription in many countries and have decades of safe use in adults and children worldwide. At MedsBase, both are available for their licensed antiparasitic uses — dispatched with discreet packaging and worldwide shipping.
If you are reading this article in the context of cancer and want to understand the drugs better, here are four principles to guide responsible decision-making:
- Consult your oncologist or GP first. If you are currently undergoing cancer treatment, drug interactions are a real concern. Ivermectin’s P-gp inhibitory activity means it could affect how other drugs are metabolised. Always disclose any additional compounds you are considering to your clinical team.
- Understand the evidence level. Preclinical evidence is not clinical proof. Reading the actual published studies — not just media summaries — will give you a far more accurate picture of where the research stands. PubMed (pubmed.ncbi.nlm.nih.gov) provides free access to the studies referenced in this article.
- Source from a reputable supplier. Medication quality varies enormously by source. Using WHO-GMP-certified generics from a reputable online pharmacy ensures you receive the correct compound at the correct dose. Browse our ivermectin range and threadworm treatments including fenbendazole at MedsBase.
- Monitor and report. If using either drug, track any side effects and report them to your healthcare provider. Liver function monitoring is advisable for anyone using fenbendazole on an extended basis beyond its standard antiparasitic course length.
Frequently Asked Questions
Q: Does fenbendazole kill cancer cells in humans?
Laboratory studies — including a 2018 paper in Scientific Reports — have shown that fenbendazole can kill cancer cells in cell culture conditions. However, killing cancer cells in a laboratory dish and achieving the same effect safely in a living human are very different challenges. There is currently no large randomised controlled trial demonstrating that fenbendazole kills cancer cells in the human body at safe doses. Research suggests biological plausibility; clinical proof has not yet been established. Anyone with a cancer diagnosis should work with a qualified medical team.
Q: Is ivermectin being studied as a cancer treatment?
Yes — ivermectin has been the subject of substantial preclinical cancer research and some early-phase clinical investigation. A 2021 review in Pharmacological Research (Tang et al.) synthesised dozens of published studies, concluding that ivermectin showed multi-targeting anti-tumour activity across multiple cancer types in laboratory models. Some clinical trials have registered on ClinicalTrials.gov to evaluate ivermectin in specific cancer contexts. As of 2026, it is not approved by any regulatory authority for cancer treatment. Research is described as promising but at an early stage.
Q: What side effects does fenbendazole have at higher doses?
At standard antiparasitic doses, fenbendazole is generally well tolerated, with occasional mild gastrointestinal side effects. At doses above those approved for antiparasitic use — which some individuals have self-administered based on online protocols — case reports have documented elevated liver enzymes and, in rare cases, clinically significant hepatotoxicity. Bone marrow suppression has also been reported with prolonged high-dose use. Liver function testing is advisable for anyone using fenbendazole beyond its standard indicated course. Always consult a clinician before using any medication above its licensed dose.
Q: Can antiparasitic drugs treat cancer?
Antiparasitic drugs cannot currently be said to “treat cancer” in the clinical sense — no antiparasitic compound is approved for cancer treatment by major regulatory bodies. However, research suggests that several antiparasitic drugs, including fenbendazole and ivermectin, interfere with biological processes that cancer cells depend on. This places them in the field of drug repurposing — investigating existing medications for new applications. Early evidence is intriguing, but patients should not substitute unproven compounds for evidence-based oncological care.
Q: What is the Joe Tippens fenbendazole cancer story?
Joe Tippens is a Texan man who, in 2016, was diagnosed with terminal small cell lung cancer and given approximately three months to live. After entering a clinical trial for pembrolizumab (an immunotherapy), he also self-administered a protocol that included fenbendazole (222mg daily for 6 days on, 1 day off), vitamin E succinate, curcumin, and CBD oil. His cancer went into apparent full remission. Because he was enrolled in an immunotherapy trial simultaneously, it is impossible to attribute his outcome to any single element of his protocol. His case prompted formal scientific investigation but is an anecdotal report, not clinical evidence.
Q: How does fenbendazole differ from ivermectin in anti-cancer mechanisms?
The two drugs act through largely distinct mechanisms. Fenbendazole primarily targets the microtubule network (disrupting cancer cell division), activates the p53 tumour suppressor pathway, and blocks glucose uptake via GLUT transporters. Ivermectin primarily targets oncogenic signalling pathways (particularly Wnt-TCF), blocks the PAK1 kinase involved in cancer invasion, disables the P-glycoprotein drug-resistance pump, and triggers mitochondria-mediated apoptosis. Their complementary mechanisms have led some researchers to speculate about combination approaches, though no human trial data on such combinations currently exists.
Q: Are fenbendazole and ivermectin safe to take together?
There is no established safety or efficacy data on using fenbendazole and ivermectin together in humans, for cancer or any other indication. Both drugs are metabolised through overlapping hepatic pathways, and both carry a liver enzyme elevation risk. Combining them without medical supervision is not advisable. If you are considering either drug — and particularly any combination — this should only be done under guidance from a qualified clinician who can monitor liver function and check for drug interactions with any other medications you are taking.
Q: Where can I find fenbendazole and ivermectin without a prescription?
Both fenbendazole and ivermectin are available without a prescription for their licensed antiparasitic indications in many countries. MedsBase stocks both for their approved uses — with WHO-GMP-certified generics, discreet packaging, and worldwide shipping. Browse our ivermectin products and fenbendazole-containing threadworm treatments for full product listings and dosage information. Note that the research discussed in this article relates to investigational cancer applications — not the licensed antiparasitic indications for which these products are sold.
The Bottom Line
The scientific interest in fenbendazole and ivermectin for cancer is real, peer-reviewed, and growing. Multiple laboratory studies have demonstrated that both drugs can interfere with cancer cell biology — disrupting cell division, blocking survival signals, reversing drug resistance, and triggering programmed cell death. The Dogra et al. Scientific Reports paper, the Tang et al. Pharmacological Research review, and several other published studies represent genuine contributions to the field of drug repurposing in oncology.
What the science cannot yet support is the claim that either drug is an effective cancer treatment in humans. The gap between promising laboratory findings and proven clinical efficacy is significant, and many compounds that show potent anti-tumour activity in cell studies fail to replicate those effects safely in human trials. Large randomised controlled trials are needed before either drug can be recommended for oncological use.
For health-conscious adults following this research, the most balanced position is to acknowledge the preclinical evidence as genuinely interesting, watch the clinical trial pipeline with curiosity, and not draw conclusions about treatment efficacy that the data does not yet support. For those with a cancer diagnosis, this research is a reason to have an informed conversation with your oncology team — not a reason to abandon conventional care.
If you are interested in fenbendazole or ivermectin for their licensed antiparasitic uses, both are available at MedsBase with worldwide shipping and discreet packaging. Browse ivermectin here or explore threadworm treatments including fenbendazole here.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Fenbendazole and ivermectin are licensed antiparasitic medications; neither is approved for the treatment of cancer by any regulatory authority. The research discussed reflects preclinical and early investigational findings — not established clinical treatments. Do not use any medication outside its licensed indication without consulting a qualified healthcare professional. If you have a cancer diagnosis or are undergoing cancer treatment, speak with your oncologist before considering any additional compounds. MedsBase is not responsible for decisions made based on the content of this article.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.